Overview

The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction

Status:
Not yet recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

300 STIMI patients with LV systolic dysfunction will be divided into two equal groups (Group I (Study arm, n=150); will receive dapagliflozin plus conventional therapy and group (II) Control arm (n=150); will receive conventional therapy only to detect an improvement in the LVEF by ≥ 5

Phase:

N/A

Details

Lead Sponsor:

Assiut University

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Adrenergic beta-Antagonists
Angiotensin II
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensinogen
Aspirin
Clopidogrel
Dapagliflozin
Diuretics
Enzyme Inhibitors
Giapreza
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mineralocorticoid Receptor Antagonists
Mineralocorticoids
Ticagrelor